Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients ...Middle East

DURHAM, N.C. and BEIJING, Aug. 24, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical need and large public health burden, today announced...

Hence then, the article about brii biosciences announces positive data from the phase 3 activ 2 trial evaluating combination brii 196 and brii 198 in non hospitalized covid 19 patients was published today ( Wednesday 25/08/2021 - 03:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients )

Also on site :

• José Leclerc Targeting July Return
• Serena Williams models swimsuit with slippers after weight loss medication backlash: ‘I’m perfectly me’
• Live Nation Antitrust Trial to Resume Monday as Company Fails to Reach Settlement With States